Loading stock data…
PLUR
$2.38+0.07 (+3.03%)
After Hours$2.36-0.02 (-0.84%)· Last close Jun 9
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pluri Inc. in the Healthcare sector is trading at $2.38. Wall Street consensus targets $12.00 (1 analysts), implying a +404.2% move over the next 12 months. The stock is currently near its 52-week low of $2.22, remaining 34.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +404.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.38
Potential Downside
0%
Whystock Fair Value$2.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$12.00+404.2%
Range$12.00 – $12.00
Fundamentals
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
137.28%
Volume
Today's trading volume
6,562
Recent News
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In
We just covered the 7 Best Lab-Grown Meat Stocks to Invest In and Pluri Inc. (NASDAQ:PLUR) ranks 4th on this list. Pluri Inc. (NASDAQ:PLUR), through the highly publicized joint venture, Ever After Foods, utilizes proprietary, state-of-the-art 3D bioreactor systems to cultivate animal cells with unprecedented density and cost efficiency. While most cell-cultured companies struggle with […]
Pluri Insider Ups Holding During Year
Insiders were net buyers of Pluri Inc.'s ( NASDAQ:PLUR ) stock during the past year. That is, insiders bought more...
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executive chairman and CEO, said the company is positioning NCEL-101, developed in partnership with Eledon Pharmaceuticals Inc., as its primary long-term value driver. Twito added that the company's stem cell-derived islet platform, combined with targeted immune prote
Pluri: Fiscal Q2 Earnings Snapshot
HAIFA, Israel (AP) — Pluri Inc. PLUR) on Thursday reported a loss of $6.5 million in its fiscal second quarter. The Haifa, Israel-based company said it had a loss of 71 cents per share.
Pluri showcases cell expansion platform as Resbiomed program advances
Pluri Inc CEO Yaky Yanay joined Steve Darling from Proactive to provide deeper insight into the company’s proprietary cell expansion technology and its strategic growth across both therapeutics and food technology. Yanay noted that Pluri has invested more than two decades in developing what he described as one of the most advanced and effective cell expansion systems globally, supported by an intellectual property portfolio of approximately 250 patents. Pluri currently operates across two core verticals. The first is focused on longevity, therapeutics, and aesthetics, where the company leverages placenta-derived cells to develop innovative biological solutions. The second vertical is centered on food technology, where Pluri’s scalable platform enables the production of cultivated meat, as well as key ingredients such as coffee, cocoa, and other agricultural inputs designed to address sustainability and supply chain challenges. Yanay also told Proactive that the company has successfully completed the first phase of its collaboration with Resbiomed Technologies OOD, a European biotechnology company specializing in extracellular-matrix (ECM)–based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri’s contract development and manufacturing organization, PluriCDMO™. He explained that the initial phase of the collaboration focused on early-stage process development and feasibility assessments, all of which have now been completed. With these objectives achieved, the program is advancing into its next phase, representing a meaningful milestone in the partnership and setting the foundation for further development work. As part of the collaboration, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to assist Resbiomed in establishing robust protocols for tissue extraction, separation, and processing. These processes are designed to preserve, concentrate, and enhance endogenous collagen components, enabling the production of high-quality biological materials suitable for a broad range of regenerative medicine applications. The work builds on Pluri’s proven experience in placenta-derived manufacturing while complementing Resbiomed’s specialized focus on ECM-based biomaterials. Human collagen and collagen-rich materials are considered premium biological inputs due to strict sourcing, regulatory, and quality requirements. By combining Pluri’s scalable manufacturing capabilities with Resbiomed’s biomaterials expertise, the collaboration aims to help address these challenges and support the development of next-generation regenerative therapies. From Pluri’s perspective, the agreement highlights the growing demand for PluriCDMO™ services among companies developing advanced cell- and tissue-based technologies. Yanay emphasized that the collaboration further strengthens PluriCDMO’s position as a trusted partner for biologics and advanced biomaterials programs that require reproducibility, scalability, and rigorous manufacturing controls as they progress toward clinical and commercial development. #proactiveinvetors #nasdaq #tase #plur #yakyyanay #biotech #PluriCDMO #Resbiomed #RegenerativeMedicine #Biotechnology #ECMBiomaterials #Collagen #BiologicsManufacturing #CDMO #AdvancedTherapies #PlacentaBasedTech #TissueEngineering #LifeSciences #Bioprocessing #ProactiveInvestors